BEGIN:VCALENDAR VERSION:2.0 PRODID:-//https://takethedate.it///NONSGML kigkonsult.se iCalcreator 2.10.15// METHOD:PUBLISH BEGIN:VEVENT UID:20240329T002710CET-5901wKPehm@https://takethedate.it/ DTSTAMP:20240328T232710Z DESCRIPTION:Napoli (NA)\, Hotel Royal Continental - Via Partenope\, 38/44 d al 5 dicembre 2019 al 7 dicembre 2019\n\nRecent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treat ments for melanoma.\nThe possibility to use targeted and immune-based drug s alone\, in combination\, or in sequence\, able to improve responses to o vercome the resistance\, to potentiate the action of immune system with th e new immunomodulating antibodies\, and identification of biomarkers that can predict the response to a particular therapy\, represent actual concep ts and approaches in the clinical management of melanoma.\nMelanoma treatm ent landscape changed in 2011 with the approval of the first anti-cytotoxi c T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody\, both of which significantly imp roved overall survival.\nSince then\, improved understanding of the tumor microenvironment and tumor immuno-evasion strategies has resulted in diffe rent approaches to target and harness the immune response.\nApproval of ne w immune- and target-therapies have further improved outcomes for patients with advanced melanoma.\nThe therapies offer the opportunity for various approaches with distinct modes of action being used in combination with on e another\, as well as combined with other treatment modalities such as ra diotherapy\, electrochemotherapy and surgery.\nLatest findings in melanoma research and advances on themes of paramount importance for melanoma prev ention\, diagnosis and treatment\, will be discussed in the session dedica ted to system biology on immunotherapy\, immunogenicity and gene expressio n profiling\, in the two sessions focused on the progresses of melanoma re search on biomarkers/precision medicine and on combination strategies\, re spectively.\nConclusions will be drawn after the “Great Debate” session\, where counterpoint views from leading experts on specific controversial cl inical issues will be presented and discussed from different points of vie w:\n\nlocal or systemic treatment?\nDo we really need to treat stage IIIA patients with adjuvant?\nWhat time is better to change treatment: progress ion disease or stable disease?\nAdoptive cell therapy before or in combina tion with check point inhibitors?\nCan we stop the treatment on while resp onse?\n\nIn order to disclose and stimulate the discussion of new approach es and strategies in the field of melanoma  \;and\, based on the incre asing success of “Melanoma Bridge” events over the years since 2011\, a pa nel of international faculty will join the congress that will be held in D ecember 2019.\nPresidents of the event are Paolo A. Ascierto (National Can cer Institute\, “Fondazione G. Pascale”\, Naples\, Italy)\, Igor Puzanov ( Roswell Park Comprehensive Cancer Center\, Buffalo\, New York\, USA) and C orrado Caracò Ascierto (National Cancer Institute\, “Fondazione G. Pascale ”\, Naples\, Italy)\, who will gather with the international faculty membe rs in an interactive atmosphere which stimulates discussion and exchange o f their experience regarding the most recent advances in research and clin ical management of melanoma patients.\nQuesto evento sarà \;accreditat o per le seguenti professioni:\nBIOLOGO\nFARMACISTA \;\nINFERMIERE\nIN FERMIERE PEDIATRICO\nMEDICO CHIRURGO \;\n https://takethedate.it/Event i/15048-melanoma-bridge-2019.html DTSTART:20191205T070000Z DTEND:20191207T160000Z LOCATION:Hotel Royal Continental Napoli (Via Partenope 38/44\, Napoli) SUMMARY:Melanoma Bridge 2019 URL:https://takethedate.it/Eventi/15048-melanoma-bridge-2019.html END:VEVENT END:VCALENDAR